TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04308863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan scaffold/ MTA pulp dressing material
Description: Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulp dressing material
Description: MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
Study: NCT01608880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin ointment
Description: Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polysporin ointment
Description: Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
Study: NCT02322749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib 75mg single dose
Description: 3 blue capsules of 25 mg given as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib 75mg single dose
Description: 3 capsules of 25 mg given as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib 75mg single dose
Description: 3 capsules of 25 mg given as a single dose
Study: NCT01259947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lippia alba (Mill.) N. E. Brown ethanolic extract
Description: 1-2 drops per kilogram per day, PO, twice a day
Study: NCT02164955

Intervention type: DRUG
Intervention: IMNOVID
Description: IMNOVID (pomalidomide) as prescribed in routine clinical practice
Study: NCT00952666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUS-RALRP
Description: During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
Study: NCT02852421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single injection paravertebral block
Description: The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple injection paravertebral blocks
Description: Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level.
Study: NCT01331317

Intervention type: DRUG
Group type: OTHER
Intervention: Paricalcitol
Description: capsule, 1-2 micrograms daily for 90 days
Study: NCT02974933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib combined with pemetrexed
Description: For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
Study: NCT02374320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: injected as an axillary block
Study: NCT02391051

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR-Brachytherapy
Description: HDR-Brachytherapy 2x 13,5 Gy
Study: NCT00198991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Antileukemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Growth factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Antileukemic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teniposide
Description: Cytostatic drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CNS irradiation
Description: Cytostatic drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mediastinal Irradiation
Description: Irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation (SCT)
Description: Stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Cytostatic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cytostatic drug
Study: NCT01093846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: 300mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: 300mg every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AIN457
Description: Placebo to AIN457
Study: NCT04601740

Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT02615886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observational Control
Description: Participants will be observed and not provided any dietary supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice bran
Description: Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
Study: NCT04481139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302, oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302, oral, once daily
Study: NCT01853475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP tablets 960mg
Description: Piperaquine phosphate tablets 960mg
Study: NCT04481139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302, oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302 placebo
Description: SHR0302 placebo, oral, once daily
Study: NCT06259214

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15% HCl gel
Description: Icon , DMG, Hamburg, Germany

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: H3PO4 gel
Description: Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Er:YAG laser
Description: Fotona AT Fidelis III, Ljubljana, Slovenia
Study: NCT04416997

Intervention type: PROCEDURE
Intervention: Blood and serum samples
Description: The blood and serum samples will taken from RA patients
Study: NCT02449421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Learning Community
Description: Consultation with CPT experts to effectively use evidence-based psychotherapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fidelity-oriented Learning Community
Description: The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
Study: NCT02939209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hcl 2Mg Tab
Description: Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients may be randomized to placebo.
Study: NCT04780815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myBluTM Formulation 1
Description: 1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myBluTM Formulation 1
Description: 1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myBluTM Formulation 2
Description: 1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myBluTM Formulation 2
Description: 1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
Study: NCT03025113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen and cyclobenzaprine association
Description: The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
Study: NCT02232204

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Insomnia in ICD Patients (CBT-I-ICD)
Description: Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
Study: NCT02383069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Aerobic training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Chest physiotherapy: Flutter and muscle stretching
Study: NCT00448214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Oral
Study: NCT01239394

Intervention type: DRUG
Group type: OTHER
Intervention: ofatumumab
Description: Weekly infusion for 8 weeks
Study: NCT01853475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP tablets 1440mg
Description: Piperaquine phosphate tablets 1440mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQP tablets 1440mg
Description: Piperaquine phosphate tablets 1440mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439+TPGS 800mg
Description: OZ439+TPGS prototype formulation 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439+TPGS 800mg
Description: OZ439+TPGS prototype formulation 800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 PIB 800mg
Description: OZ439 Powder in Bottle Aqueous Solution 800mg
Study: NCT01770977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light-emitting diode therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light-emitting diode therapy
Study: NCT02619903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental cleaning
Description: Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
Study: NCT02649738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal tissue inlay
Description: A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
Study: NCT03342989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Contact Control
Description: This intervention provides social contact and mentally stimulating activities that do not target speed of processing
Study: NCT02291939

Intervention type: PROCEDURE
Intervention: Parotidectomy
Description: Surgical Intervention with the FMwand Surgical System
Study: NCT02766777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 or 24 mcg soft capsules for oral administration.
Study: NCT01911390

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bean powder
Description: Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
Study: NCT00922870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cascade
Description: Cascade treatment over 48h

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard therapy
Study: NCT00799084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse
Description: Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AVR
Description: Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
Study: NCT01223404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants are administered a placebo patch and a placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants are administered a placebo patch and a placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants are administered a placebo patch and a placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants are administered a placebo patch and a placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants are administered a placebo patch and a placebo capsule
Study: NCT01911390

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rice bran
Description: USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
Study: NCT01223404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants are administered a placebo patch and a placebo capsule
Study: NCT01911390

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control arm
Description: No bean or rice bran additive in smoothie or muffin.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bean powder and rice bran
Description: Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
Study: NCT03856983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point light display
Description: Experimental group who will do usual rehabilitation and visualization of point-light human actions
Study: NCT01223404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
Study: NCT02182050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 ES low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 ES high dose
Study: NCT01223404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
Study: NCT02182050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BIBF 1120 ES
Study: NCT03217695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Yoga Arm
Study: NCT04694170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional therapy
Description: Using conventional physiotherapy together with additional yoga exercising and regimen restriction acc to TCM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: Using conventional physiotherapy only.
Study: NCT01223404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
Study: NCT04694170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Using conventional physiotherapy only.
Study: NCT00941070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo pelvic external beam radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG-PET/CT
Study: NCT01279928

Intervention type: PROCEDURE
Intervention: Video Nailfold Capillaroscopy
Description: Single session of video Nailfold Capillaroscopy wit KKK technology
Study: NCT01223404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
Study: NCT00362947

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LMWH parnaparin subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH parnaparin subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH parnaparin subcutaneously
Study: NCT02467361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
Study: NCT01279928

Intervention type: DEVICE
Intervention: Ambulatory 24 hr Blood Pressure Monitoring
Description: 24 hr upper arm cuff measurement of Blood Pressure

Intervention type: PROCEDURE
Intervention: Fundoscopy of eyes
Description: examination of microvascular health of eye with the use of opthalmoscope

Intervention type: PROCEDURE
Intervention: Laser Doppler Flowmetry
Description: Examination of vascular flow
Study: NCT03174431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continence Pessary
Description: Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poise Impressa (Disposable Intravaginal Device)
Description: In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.